ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

ECG Interpretation: Everything You Need to Know to Understand and In…

Houston Methodist DeBakey Heart and Vascular Center

A. Dave

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

SGLT2 Inhibition in 2024: Use in Heart Failure and Mechanism of Acti…

28th Annual Heart Failure 2024: An Update on Therapy

M. Packer

EHRA 2024: Ongoing Clinical Investigations with Cardiac Contractilit…

CCM® Therapy

N. Varma

EHRA 2024: Real-World Experience with Cardiac Contractility Modulati…

CCM® Therapy

J. Kuschyk

HFpEF in Women

Scripps Health

B. Borlaug

EHRA 2024: Cardiac Contractility Modulation: Innovative Therapy for …

CCM® Therapy

V. Reddy, N. Varma, K. Kuck, J. Kuschyk, N. Aspromonte

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Donation After Cardiac Death: A New Paradigm for Organ Donation in H…

Cedars Sinai

P. Catarino

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

Cardiotoxicity: Anthracyclines

Scripps Health

M. Davis

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

EHRA 2024: Unmet Medical Needs in Heart Failure Management: Can Devi…

CCM® Therapy

N. Aspromonte